STAAR Surgical vs Glaukos: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

STAAR Surgical Company (STAA)

Q3 202617 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

August 202617 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

Latest17 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

Glaukos Corp (GKOS)

Q3 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

September 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

Latest30 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.